The 5 most-read breast cancer articles on AJMC.com this year included FDA approvals, emerging therapies for metastatic breast ...
Orlowski Calls Linvoseltamab Results “the Best Single Agent Data Ever In the History of Myeloma”
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
Tom Kim, MD, of Sound Long-Term Care Management, discusses how serious illness and care coordination set these ACO patients ...
The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted ...
Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...
FLAMeS, a new convolutional neural network, enhances MS lesion segmentation accuracy using only T2-weighted FLAIR images, ...
Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...
New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...
Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...
Panelists discuss how schizophrenia typically evolves through distinct phases—from first-episode psychosis to chronic illness ...
Panelists discuss how relapse is one of the most significant challenges in schizophrenia management, often resulting in ...
These top 5 stories underscore how 2025 was a year of constant friction at the intersection of public health and political ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback